Glargine versus NPH insulin: Efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes—The glargine and aspart study (GLASS)

• Published in: Diabetes research and clinical practice 2007-08, Vol.77 (2), p.215-222
• Main Authors: Chatterjee, S, Jarvis-Kay, J, Rengarajan, T, Lawrence, I.G, McNally, P.G, Davies, M.J
• Format: Article
• Language: English
• Subjects: Endocrinology & Metabolism; HbA1c; Insulin analogues; Insulin aspart; Insulin glargine; Type 1 diabetes
• ISSN: 0168-8227; 1872-8227
• DOI: 10.1016/j.diabres.2006.11.002

Abstract The aim of the study was to compare the efficacy of insulin glargine and aspart with NPH insulin and aspart in a basal bolus regimen in type 1 diabetes. In this 36-week randomised open-label two-period cross-over trial, subjects received 16 weeks’ treatment with either once-daily insulin glargine or twice-daily NPH insulin after 4-week run-in. Primary outcome was HbA1c and secondary outcomes were fasting plasma glucose (FPG), weight change, incidence of hypoglycaemia, effect on lipid profile and patient satisfaction. Sixty patients with type 1 diabetes were recruited (33 male, mean age 42.7 years, mean HbA1c 8.53%) with 53 completing the study. At completion, HbA1c was lower with glargine and aspart than with NPH and aspart (8.07% versus 8.26%, difference −0.19 [95% CI 0.37–0.01]%, p = 0.04). FPG was significantly different between glargine and NPH ( p = 0.002), with mean FPG on glargine 3 mmol/L lower than on NPH at the end of the study. There were no differences in hypoglycaemia rate ( p = 0.63), weight ( p = 0.45) or lipid profile ( p = 0.18). Patient satisfaction was greater with glargine (DTSQ, p = 0.001). Three patients discontinued as they wished to remain on glargine. We suggest that glargine combined with aspart is an effective basal bolus regimen in type 1 diabetes.